publication date: Sep. 20, 2019
SU2C to spend $6 million on two trials in breast, prostate cancer
Stand Up To Cancer (SU2C) is spending $6 million on two clinical trial teams to research triple-negative breast cancer in women and metastatic prostate cancer in men.
The effort is funded by Genentech, a member of the Roche Group, through the SU2C Catalyst initiative.
Through SU2C Catalyst, Genentech has offered more than a dozen approved or investigational medicines to be studied in combination with other treatments, including medicines from other pharmaceutical companies, in support of clinical trials focusing on new uses. Genentech medicines to be used in these projects include atezolizumab (Tecentriq), a PD-L1 inhibitor, and ipatasertib, an investigational medicine that inhibits a key component of the PI3K/AKT cellular signaling pathway.
The first team is investigating the combination of ipatasertib and atezolizumab to prevent recurrence in triple-negative breast cancer. Elizabeth A. Mittendorf, director of the breast immuno-oncology program at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, and Angela DeMichele, co-leader of the breast cancer research program at the Abramson Cancer Center of the University of Pennsylvania, will lead the team.
The team will use blood analysis, or liquid biopsy, to detect micrometastatic disease before it can take hold in distant organs and treat it with a combination of ipatasertib and atezolizumab medicines.
“We hope to target microscopic cancer cells with medicines that are specifically designed to help inhibit immune escape mechanisms or signaling that leads to proliferation of cancer,” Mittendorf said in a statement.
The second clinical trial team, led by radiation oncologist Sean M. McBride and medical oncologist Dana E. Rathkopf, both of Memorial Sloan Kettering Cancer Center, … Continue reading SU2C to spend $6 million on two trials in breast, prostate cancer
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.